Aileen I. Fernandez, PhD

home / authors / aileen-i-fernandez-phd

Articles

Aileen I. Fernandez, PhD

Dr. Fernandez on the Utility of Trastuzumab Deruxtecan in HER2-Low Breast Cancer

Aileen I. Fernandez, PhD
December 22nd 2021

Aileen I. Fernandez, PhD, discusses the utility of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.

Read More

Aileen I. Fernandez, PhD

Dr. Fernandez on the Need to Refine Immunohistochemistry Testing in HER2+ Breast Cancer

Aileen I. Fernandez, PhD
December 14th 2021

Aileen I. Fernandez, PhD, discusses the need to refine immunohistochemistry testing in HER2-positive breast cancer.

Read More

Aileen I. Fernandez, PhD

Dr. Fernandez on the Results of a Study Examining Low HER2 Expression in Breast Cancer

Aileen I. Fernandez, PhD
December 8th 2021

Aileen I. Fernandez, PhD, discusses the results of a study examining low HER2 expression in breast cancer.

Read More

Latest Updated Articles

Alexis LeVee, MD
Published: May 14th 2025 | Updated: May 30th 2025
Breast Cancer Experts Bookmark Top Abstracts to Watch at the 2025 ASCO Annual Meeting
Arielle Heeke, MD
Published: May 2nd 2025 | Updated: May 6th 2025
Adjuvant CDK4/6 Inhibition Gains Further Ground in HR+/HER2– Early Breast Cancer With Ribociclib Approval
Bridging Data and Expert Insights: Paving the Way for Improved CLL Outcomes
Published: March 10th 2025 | Updated: April 25th 2025
Bridging Data and Expert Insights: Paving the Way for Improved CLL Outcomes
Núria Agustí Garcia, MD
Published: April 21st 2025 | Updated: April 23rd 2025
Dr Agustí on Patient Eligibility for Evaluating Chemoradiotherapy vs Radiotherapy Alone in Intermediate-Risk Cervical Cancer
Prognostic and predictive role of circulating tumor DNA (ctDNA) in stage III colon cancer treated with celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Published: April 16th 2025 | Updated: April 18th 2025
Prognostic and Predictive Role of Circulating Tumor DNA (ctDNA) in Stage III Colon Cancer Treated With Celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer
Published: February 18th 2025 | Updated: April 17th 2025
Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer